BIO vs JAZZ: fair value comparison
Bio-Rad Laboratories, Inc. and Jazz Pharmaceuticals plc · Updated 2026-08-31
BIO currently screens as overvalued while JAZZ screens as fairly valued. Within Healthcare, JAZZ currently sits closer to the top of our discount ranking.
| BIO | JAZZ | |
|---|---|---|
| Verdict | Overvalued | Fairly valued |
| Last price | $330.01 | $251.58 |
| 12-month range | $256.55–$334.71 | $129.66–$251.58 |
| Sector rank | #89 of 113 Healthcare | #84 of 113 Healthcare |
| Quality grade | B | B |
| Momentum grade | — | A |
| Leverage | Low | Moderate |
| Margin trend | Contracting | Stable |
| Revenue growth | Declining | Modest |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | — | Fairly Valued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BIO fair value analysis · JAZZ fair value analysis